

Tapan M Kadia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7129875/publications.pdf>

Version: 2024-02-01

252
papers

13,343
citations

28190

55
h-index

32761

100
g-index

254
all docs

254
docs citations

254
times ranked

10096
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. <i>Cancer Discovery</i> , 2016, 6, 1106-1117. | 7.7 | 799 |
| 2 | Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103. | 13.9 | 388 |
| 3 | Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , 2019, 9, 370-383. | 7.7 | 380 |
| 4 | Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <i>Blood</i> , 2013, 121, 4655-4662. | 0.6 | 355 |
| 5 | Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. <i>Blood</i> , 2010, 116, 4422-4429. | 0.6 | 336 |
| 6 | Clinical experience with the BCL-2 inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018, 93, 401-407. | 2.0 | 336 |
| 7 | Acute myeloid leukemia: current progress and future directions. <i>Blood Cancer Journal</i> , 2021, 11, 41. | 2.8 | 313 |
| 8 | Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. <i>Journal of Hematology and Oncology</i> , 2019, 12, 1. | 6.9 | 257 |
| 9 | Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. <i>Blood</i> , 2016, 127, 1863-1869. | 0.6 | 253 |
| 10 | Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 1547-1555. | 5.1 | 245 |
| 11 | Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. <i>American Journal of Hematology</i> , 2015, 90, 732-736. | 2.0 | 242 |
| 12 | Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. <i>Journal of Clinical Oncology</i> , 2010, 28, 392-397. | 0.8 | 231 |
| 13 | Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. <i>Blood</i> , 2017, 129, 1275-1283. | 0.6 | 214 |
| 14 | Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. <i>Cancer Discovery</i> , 2020, 10, 506-525. | 7.7 | 212 |
| 15 | 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , the, 2020, 7, e724-e736. | 2.2 | 201 |
| 16 | TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. <i>Cancer</i> , 2016, 122, 3484-3491. | 2.0 | 200 |
| 17 | Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 240-248. | 5.1 | 192 |
| 18 | Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 653-661. | 1.7 | 191 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778. | 0.8 | 173 |
| 20 | Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2012, 30, 2204-2210. | 0.8 | 158 |
| 21 | Hyper- CVAD plus ponatinib versus hyper- CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2016, 122, 3650-3656. | 2.0 | 156 |
| 22 | Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797. | 0.8 | 156 |
| 23 | Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2015, 90, 276-281. | 2.0 | 139 |
| 24 | Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 230. | 3.4 | 124 |
| 25 | Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , 2016, 127, 1269-1275. | 0.6 | 119 |
| 26 | Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. <i>Cancer</i> , 2017, 123, 4391-4402. | 2.0 | 114 |
| 27 | Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320. | 2.5 | 106 |
| 28 | Prognostic and therapeutic impacts of mutant <i>TP53</i> variant allelic frequency in newly diagnosed acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 5681-5689. | 2.5 | 105 |
| 29 | Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e480-e488. | 2.2 | 103 |
| 30 | Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 392-400. | 1.2 | 102 |
| 31 | Sorafenib Combined with 5-azacytidine in Older Patients with Untreated <i>FLT3</i> -ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1136-1141. | 2.0 | 95 |
| 32 | Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). <i>Cancer</i> , 2014, 120, 3660-3668. | 2.0 | 91 |
| 33 | Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018, 124, 4044-4055. | 2.0 | 88 |
| 34 | Genomic context and <i>TP53</i> allele frequency define clinical outcomes in <i>TP53</i> -mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495. | 2.5 | 86 |
| 35 | Clinical implications of <i>TP53</i> mutations in myelodysplastic syndromes treated with hypomethylating agents. <i>Oncotarget</i> , 2016, 7, 14172-14187. | 0.8 | 86 |
| 36 | Triplet therapy with venetoclax, <i>FLT3</i> inhibitor and decitabine for <i>FLT3</i> -mutated acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 25. | 2.8 | 85 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. <i>Blood Advances</i> , 2019, 3, 922-933. | 2.5 | 84 |
| 38 | Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e29-e37. | 2.2 | 84 |
| 39 | Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. <i>Blood Advances</i> , 2017, 1, 1312-1323. | 2.5 | 83 |
| 40 | Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e552-e561. | 2.2 | 81 |
| 41 | Outcomes of TP53 mutant acute myeloid leukemia with decitabine and venetoclax. <i>Cancer</i> , 2021, 127, 3772-3781. | 2.0 | 80 |
| 42 | De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. <i>Cancer</i> , 2021, 127, 2049-2061. | 2.0 | 79 |
| 43 | Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2018, 124, 2758-2765. | 2.0 | 78 |
| 44 | BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. <i>Leukemia</i> , 2017, 31, 678-687. | 3.3 | 77 |
| 45 | Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2642. | 0.8 | 77 |
| 46 | RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. <i>Blood</i> , 2019, 134, 59-73. | 0.6 | 75 |
| 47 | HyperCVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99. | 2.0 | 74 |
| 48 | Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. <i>Cancer</i> , 2021, 127, 1186-1207. | 2.0 | 74 |
| 49 | Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory T-cell acute lymphoblastic leukemia. <i>Cancer</i> , 2017, 123, 294-302. | 2.0 | 70 |
| 50 | Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 765-774. | 2.0 | 69 |
| 51 | Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421. | 2.2 | 66 |
| 52 | Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 426-435. | 2.0 | 63 |
| 53 | Inotuzumab ozogamicin in combination with low-intensity chemotherapy (miniHCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019, 125, 2579-2586. | 2.0 | 63 |
| 54 | Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218. | 1.3 | 63 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG+GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2014, 89, 964-968. | 2.0 | 62 |
| 56 | Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. <i>Leukemia</i> , 2021, 35, 3282-3286. | 3.3 | 61 |
| 57 | Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 2607. | 5.8 | 61 |
| 58 | Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291. | 2.0 | 59 |
| 59 | Failure of Hypomethylating Agent-Based Therapy in Myelodysplastic Syndromes. <i>Seminars in Oncology</i> , 2011, 38, 682-692. | 0.8 | 58 |
| 60 | Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. <i>Blood Cancer Journal</i> , 2019, 9, 4. | 2.8 | 57 |
| 61 | Treating Leukemia in the Time of COVID-19. <i>Acta Haematologica</i> , 2021, 144, 132-145. | 0.7 | 57 |
| 62 | Maintenance therapy in AML: The past, the present and the future. <i>American Journal of Hematology</i> , 2019, 94, 1254-1265. | 2.0 | 56 |
| 63 | Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883. | 2.5 | 56 |
| 64 | A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2018, 93, 277-285. | 2.0 | 54 |
| 65 | Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. <i>Acta Haematologica</i> , 2020, 143, 567-573. | 0.7 | 53 |
| 66 | Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. <i>Blood Advances</i> , 2017, 1, 1546-1550. | 2.5 | 52 |
| 67 | Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 155-162.e1. | 0.2 | 51 |
| 68 | Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. <i>American Journal of Hematology</i> , 2020, 95, 612-622. | 2.0 | 51 |
| 69 | Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with <i>NPM1</i> and <i>FLT3</i> internal tandem duplication genotypes. <i>Cancer</i> , 2019, 125, 1091-1100. | 2.0 | 50 |
| 70 | Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134. | 2.6 | 50 |
| 71 | Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017, 123, 459-467. | 2.0 | 49 |
| 72 | Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). <i>Blood Cancer Journal</i> , 2022, 12, 5. | 2.8 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. <i>Leukemia Research</i> , 2015, 39, 1367-1374. | 0.4 | 48 |
| 74 | Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1755-1763. | 2.9 | 48 |
| 75 | Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2022, 12, 10. | 2.8 | 48 |
| 76 | Toward Individualized Therapy in Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2015, 1, 820. | 3.4 | 47 |
| 77 | Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. <i>Cancer</i> , 2017, 123, 3050-3060. | 2.0 | 47 |
| 78 | Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 1-8. | 1.0 | 47 |
| 79 | Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≥ 60 years with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2013, 88, 961-966. | 2.0 | 46 |
| 80 | <i>TP53</i> copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. <i>Blood</i> , 2022, 140, 58-72. | 0.6 | 46 |
| 81 | Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. <i>Cancer</i> , 2017, 123, 4851-4859. | 2.0 | 45 |
| 82 | Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533. | 2.2 | 43 |
| 83 | Poor outcomes associated with <i>der(22)t(9;22)</i> and <i>9p</i> in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. <i>American Journal of Hematology</i> , 2017, 92, 238-243. | 2.0 | 41 |
| 84 | Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857. | 0.8 | 41 |
| 85 | Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2015, 121, 2375-2382. | 2.0 | 40 |
| 86 | Progress in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 139-151. | 0.2 | 40 |
| 87 | Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2018, 93, 84-90. | 2.0 | 40 |
| 88 | Outcomes in patients with newly diagnosed <i>TP53</i> -mutated acute myeloid leukemia with or without venetoclax-based therapy. <i>Cancer</i> , 2021, 127, 3541-3551. | 2.0 | 40 |
| 89 | IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 639387. | 1.3 | 39 |
| 90 | Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017, 92, 599-606. | 2.0 | 38 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3 internal tandem duplication mutation positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766. | 2.0 | 38 |
| 92 | A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4430-4439. | 2.0 | 37 |
| 93 | Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1618. | 1.8 | 37 |
| 94 | A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2489-2492. | 3.3 | 37 |
| 95 | The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 691-700. | 3.3 | 37 |
| 96 | High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. <i>Blood Advances</i> , 2022, 6, 4006-4014. | 2.5 | 37 |
| 97 | Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. <i>Cancer</i> , 2012, 118, 5550-5559. | 2.0 | 36 |
| 98 | Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2012, 157, 312-320. | 1.2 | 36 |
| 99 | Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 845-850. | 2.0 | 36 |
| 100 | Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients. <i>Journal of Clinical Oncology</i> , 2018, 36, 7014-7014. | 0.8 | 36 |
| 101 | Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. <i>American Journal of Hematology</i> , 2015, 90, 193-196. | 2.0 | 35 |
| 102 | The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. <i>Blood</i> , 2017, 130, 723-723. | 0.6 | 35 |
| 103 | Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast-Phase Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 244-251. | 0.2 | 34 |
| 104 | Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. <i>Leukemia</i> , 2018, 32, 2388-2398. | 3.3 | 34 |
| 105 | Prognosis of patients with intermediate risk IPSS myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS. <i>American Journal of Hematology</i> , 2018, 93, 1245-1253. | 2.0 | 34 |
| 106 | A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2021, 106, 2121-2130. | 1.7 | 34 |
| 107 | Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2489-2499. | 2.0 | 34 |
| 108 | A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 3761-3771. | 2.0 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. <i>Blood</i> , 2022, 139, 907-921. | 0.6 | 34 |
| 110 | Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 2193-2205. | 2.0 | 33 |
| 111 | Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. <i>Blood Advances</i> , 2021, 5, 2156-2164. | 2.5 | 33 |
| 112 | Prognostic factors for progression in patients with Philadelphia chromosome \hat{e} positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. <i>Cancer</i> , 2021, 127, 2648-2656. | 2.0 | 33 |
| 113 | <sc>Treatment \hat{e} free</sc> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 856-864. | 2.0 | 33 |
| 114 | Hypomethylating agent and venetoclax with FLT3 inhibitor \hat{e} triple \hat{e} therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77. | 2.8 | 33 |
| 115 | Prognostic significance of baseline <i>FLT3</i> \hat{e} TD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991. | 2.0 | 32 |
| 116 | Targeting nuclear \hat{I}^2 -catenin as therapy for post-myeloproliferative neoplasm secondary AML. <i>Leukemia</i> , 2019, 33, 1373-1386. | 3.3 | 32 |
| 117 | Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. <i>Blood Cancer Journal</i> , 2021, 11, 162. | 2.8 | 32 |
| 118 | More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 421-432. | 1.8 | 31 |
| 119 | Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. <i>Blood</i> , 2021, 138, 1373-1377. | 0.6 | 31 |
| 120 | Venetoclax combined with <sc>FLAG \hat{e} IDA</sc> induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043. | 2.0 | 31 |
| 121 | Impact of comorbidities by ACE \hat{e} 27 in the revised \hat{e} PSS for patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2014, 89, 509-516. | 2.0 | 30 |
| 122 | Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review. <i>Expert Review of Hematology</i> , 2017, 10, 433-448. | 1.0 | 30 |
| 123 | Dorsal column myelopathy after intrathecal chemotherapy for leukemia. <i>American Journal of Hematology</i> , 2017, 92, 155-160. | 2.0 | 30 |
| 124 | Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. <i>Cancer</i> , 2020, 126, 1152-1160. | 2.0 | 29 |
| 125 | Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 6117-6126. | 2.5 | 29 |
| 126 | Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1288-1295. | 2.0 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with <i>NPM1</i> mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1054-1063. | 1.2 | 28 |
| 128 | Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. <i>American Journal of Hematology</i> , 2015, 90, 769-773. | 2.0 | 27 |
| 129 | Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. <i>Cancer</i> , 2018, 124, 4192-4201. | 2.0 | 27 |
| 130 | A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second and third generation tyrosine kinase inhibitors. <i>Cancer Medicine</i> , 2018, 7, 5457-5469. | 1.3 | 27 |
| 131 | Mechanistic basis and efficacy of targeting the β -catenin/TCF7L2/JMJD6/c-Myc axis to overcome resistance to BET inhibitors. <i>Blood</i> , 2020, 135, 1255-1269. | 0.6 | 27 |
| 132 | Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. <i>Leukemia</i> , 2018, 32, 2512-2518. | 3.3 | 26 |
| 133 | Philadelphia chromosome positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 1388-1395. | 2.0 | 26 |
| 134 | EVII dysregulation: impact on biology and therapy of myeloid malignancies. <i>Blood Cancer Journal</i> , 2021, 11, 64. | 2.8 | 26 |
| 135 | Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360. | 2.2 | 26 |
| 136 | Molecular pathogenesis of acquired aplastic anemia. <i>European Journal of Haematology</i> , 2019, 102, 103-110. | 1.1 | 25 |
| 137 | The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia negative B cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020, 95, 144-150. | 2.0 | 25 |
| 138 | Prediction of early (4 week) mortality in acute myeloid leukemia with intensive chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 68-78. | 2.0 | 25 |
| 139 | Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. <i>Lancet Haematology</i> , 2015, 2, e12-e20. | 2.2 | 24 |
| 140 | Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. <i>American Journal of Hematology</i> , 2015, 90, E139-41. | 2.0 | 24 |
| 141 | Long term follow up of salvage therapy using a combination of inotuzumab ozogamicin and mini hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038. | 2.0 | 24 |
| 142 | Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. <i>Blood Cancer Journal</i> , 2021, 11, 98. | 2.8 | 24 |
| 143 | Ten day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score matched analysis. <i>Cancer</i> , 2021, 127, 4213-4220. | 2.0 | 24 |
| 144 | Outcomes of acute lymphoblastic leukemia with <i>KMT2A</i> (<i>MLL</i>) rearrangement: the MD Anderson experience. <i>Blood Advances</i> , 2021, 5, 5415-5419. | 2.5 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. <i>Cancer</i> , 2018, 124, 2534-2540. | 2.0 | 23 |
| 146 | <p>Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8817-8828. | 0.9 | 23 |
| 147 | Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1000-1007. | 2.0 | 23 |
| 148 | Phase 1 study of combinatorial sorafenib, <sc>Gâ€CSF</sc>, and plerixafor treatment in relapsed/refractory, <sc>FLT3â€ITD</sc>â€mutated acute myelogenous leukemia patients. <i>American Journal of Hematology</i> , 2020, 95, 1296-1303. | 2.0 | 22 |
| 149 | Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. <i>Blood Cancer Journal</i> , 2021, 11, 60. | 2.8 | 22 |
| 150 | Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429. | 3.3 | 22 |
| 151 | Phase II study of methotrexate, vincristine, pegylatedâ€asparaginase, and dexamethasone (<sc>MO</sc>p<sc>AD</sc>) in patients with relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 120-124. | 2.0 | 21 |
| 152 | Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1855-1866. | 2.0 | 21 |
| 153 | Longâ€term results of frontline dasatinib in chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 1502-1511. | 2.0 | 21 |
| 154 | Outcomes with lower intensity therapy in<i>TP53</i>-mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2238-2241. | 0.6 | 20 |
| 155 | Response kinetics and factors predicting survival in core-binding factor leukemia. <i>Leukemia</i> , 2018, 32, 2698-2701. | 3.3 | 20 |
| 156 | Clonal hematopoiesis of indeterminate potentialâ€associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. <i>Cancer</i> , 2019, 125, 2233-2241. | 2.0 | 19 |
| 157 | Decitabine and venetoclax for <i><sc>IDH1/2</sc>â€</i> mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E154-E157. | 2.0 | 19 |
| 158 | Impact of frontline treatment approach on outcomes of myeloid blast phase CML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 94. | 6.9 | 19 |
| 159 | Only <i>SF3B1</i> mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. <i>Cancer</i> , 2021, 127, 3552-3565. | 2.0 | 19 |
| 160 | Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 286-286. | 0.6 | 19 |
| 161 | Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). <i>Blood</i> , 2019, 134, 290-290. | 0.6 | 19 |
| 162 | Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 163-168.e2. | 0.2 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | <i>TP53</i> mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. <i>Cancer</i> , 2017, 123, 3717-3724. | 2.0 | 18 |
| 164 | Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. <i>Journal of Hematology and Oncology</i> , 2020, 13, 132. | 6.9 | 18 |
| 165 | Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. <i>Cancer</i> , 2012, 118, 5819-5822. | 2.0 | 17 |
| 166 | Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 924-928. | 2.0 | 17 |
| 167 | P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with <i>FLT3</i> internal tandem duplication and worse relapse-free survival. <i>American Journal of Hematology</i> , 2018, 93, 1376-1383. | 2.0 | 17 |
| 168 | NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E158-E160. | 2.0 | 17 |
| 169 | An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E229-E232. | 2.0 | 17 |
| 170 | Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. <i>Blood</i> , 2020, 136, 18-20. | 0.6 | 17 |
| 171 | Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. <i>American Journal of Hematology</i> , 2022, 97, E62. | 2.0 | 17 |
| 172 | Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. <i>Blood Advances</i> , 2022, 6, 3027-3035. | 2.5 | 17 |
| 173 | Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 1494-1499. | 3.3 | 16 |
| 174 | Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies. <i>Clinical Infectious Diseases</i> , 2022, 75, 1503-1510. | 2.9 | 16 |
| 175 | Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. <i>Cancer</i> , 2021, 127, 2641-2647. | 2.0 | 15 |
| 176 | Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. <i>Blood</i> , 2019, 134, 2637-2637. | 0.6 | 15 |
| 177 | Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. <i>American Journal of Hematology</i> , 2022, 97, 329-337. | 2.0 | 15 |
| 178 | Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. <i>Cancer</i> , 2019, 125, 3219-3224. | 2.0 | 14 |
| 179 | Long-term results of a phase 2 trial of nilotinib 400mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2020, 126, 1448-1459. | 2.0 | 14 |
| 180 | A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. <i>Acta Haematologica</i> , 2022, 145, 529-536. | 0.7 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Clinical outcomes in adult patients with aplastic anemia: A single institution experience. <i>American Journal of Hematology</i> , 2017, 92, 1295-1302. | 2.0 | 13 |
| 182 | Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 914-924. | 2.0 | 13 |
| 183 | Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. <i>Journal of Hematology and Oncology</i> , 2022, 15, 12. | 6.9 | 13 |
| 184 | Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 3402-3410. | 0.6 | 12 |
| 185 | Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2018, 132, 36-36. | 0.6 | 12 |
| 186 | Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2640-2640. | 0.6 | 12 |
| 187 | Prediction of survival with intensive chemotherapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 865-876. | 2.0 | 12 |
| 188 | A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2161-2170. | 0.6 | 12 |
| 189 | First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). <i>Leukemia and Lymphoma</i> , 2020, 61, 445-449. | 0.6 | 11 |
| 190 | Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 2647-2647. | 0.6 | 11 |
| 191 | Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020, 136, 42-43. | 0.6 | 11 |
| 192 | Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.. <i>Blood</i> , 2012, 120, 2630-2630. | 0.6 | 11 |
| 193 | Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2017, 130, 815-815. | 0.6 | 11 |
| 194 | Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2023, 98, . | 2.0 | 11 |
| 195 | Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e871-e882. | 0.2 | 10 |
| 196 | Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, 734-739. | 2.0 | 10 |
| 197 | Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3 Δ ITD and IDH mutations. <i>Cancer</i> , 2021, 127, 381-390. | 2.0 | 10 |
| 198 | Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2184-2192. | 0.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Development of TP53 mutations over the course of therapy for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1420-1428. | 2.0 | 10 |
| 200 | Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 17-19. | 0.6 | 10 |
| 201 | Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. <i>American Journal of Hematology</i> , 2020, 95, E225-E228. | 2.0 | 9 |
| 202 | Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). <i>American Journal of Hematology</i> , 2021, 96, E246-E249. | 2.0 | 9 |
| 203 | Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 574-582. | 2.0 | 9 |
| 204 | Resistance to targeted therapies: delving into FLT3 and IDH. <i>Blood Cancer Journal</i> , 2022, 12, . | 2.8 | 9 |
| 205 | The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. <i>Leukemia and Lymphoma</i> , 2020, 61, 536-545. | 0.6 | 8 |
| 206 | The clinical impact of time to response in de novo accelerated phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1127-1134. | 2.0 | 8 |
| 207 | Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E50-E53. | 2.0 | 8 |
| 208 | Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 7034-7034. | 0.8 | 8 |
| 209 | Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 2736-2745. | 2.0 | 8 |
| 210 | Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. <i>Leukemia</i> , 2020, 34, 2914-2924. | 3.3 | 7 |
| 211 | Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. <i>Blood</i> , 2018, 132, 663-663. | 0.6 | 7 |
| 212 | Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2541-2541. | 0.6 | 7 |
| 213 | Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML) Tj ETQq1_1_0.784314 rgBT | 0.8 | 7 |
| 214 | Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. <i>American Journal of Hematology</i> , 2022, 97, . | 2.0 | 7 |
| 215 | A dynamic factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 1127-1134. | 2.0 | 7 |
| 216 | Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 491-499. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2020, 38, 7539-7539. | 0.8 | 6 |
| 218 | Treatment-free remission in chronic myeloid leukemia. Clinical Advances in Hematology and Oncology, 2019, 17, 686-696. | 0.3 | 6 |
| 219 | Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1176-1184. | 1.1 | 6 |
| 220 | Blinatumomab is associated with favorable outcomes in patients with Bâ€cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10 ⁻⁴ and higher. American Journal of Hematology, 2022, 97, 1135-1141. | 2.0 | 6 |
| 221 | Phase 1/2 study of DFPâ€10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer, 2019, 125, 1665-1673. | 2.0 | 5 |
| 222 | Phase 2 study of lenalidomide maintenance for patients with highâ€risk acute myeloid leukemia in remission. Cancer, 2021, 127, 1894-1900. | 2.0 | 5 |
| 223 | Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer Journal, 2021, 11, 52. | 2.8 | 5 |
| 224 | Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer, 2021, 127, 3113-3124. | 2.0 | 5 |
| 225 | Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood, 2020, 136, 7-9. | 0.6 | 5 |
| 226 | Which FLT3 Inhibitor for Treatment of AML?. Current Treatment Options in Oncology, 2022, 23, 359-380. | 1.3 | 5 |
| 227 | Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. American Journal of Hematology, 2019, 94, E188-E190. | 2.0 | 4 |
| 228 | Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2775-2777. | 0.6 | 4 |
| 229 | Identifying effective drug combinations for patients with acute myeloid leukemia. Expert Review of Anticancer Therapy, 2020, 20, 591-601. | 1.1 | 4 |
| 230 | Clinical value of event-free survival in acute myeloid leukemia. Blood Advances, 2020, 4, 1690-1699. | 2.5 | 4 |
| 231 | Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer, 2021, 127, 4421-4431. | 2.0 | 4 |
| 232 | Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. Blood, 2018, 132, 34-34. | 0.6 | 4 |
| 233 | Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2020, 136, 11-12. | 0.6 | 4 |
| 234 | Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer Journal, 2022, 12, 23. | 2.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Urgent cytorreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894. | 2.0 | 4 |
| 236 | Multiple recurrent extramedullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase. <i>American Journal of Hematology</i> , 2013, 88, 433-434. | 2.0 | 3 |
| 237 | PET-CT in AML-related hemophagocytic lymphohistiocytosis. <i>Leukemia and Lymphoma</i> , 2018, 59, 1486-1489. | 0.6 | 3 |
| 238 | Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1012-1015. | 0.6 | 3 |
| 239 | FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. <i>American Journal of Hematology</i> , 2021, 96, E275-E279. | 2.0 | 3 |
| 240 | Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. <i>Blood</i> , 2020, 136, 30-33. | 0.6 | 3 |
| 241 | Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 5011-5011. | 0.6 | 3 |
| 242 | Alemtuzumab in T-cell large granular lymphocyte leukaemia. <i>Lancet Haematology</i> , 2016, 3, e4-e5. | 2.2 | 2 |
| 243 | Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E357-E360. | 2.0 | 2 |
| 244 | Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia. <i>Future Oncology</i> , 2019, 15, 3885-3894. | 1.1 | 2 |
| 245 | Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). <i>American Journal of Hematology</i> , 2020, 95, E326-E329. | 2.0 | 2 |
| 246 | Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2020, 21, 34. | 1.3 | 2 |
| 247 | Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. <i>Leukemia and Lymphoma</i> , 2021, , 1-5. | 0.6 | 2 |
| 248 | Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. <i>Blood</i> , 2019, 134, 2582-2582. | 0.6 | 2 |
| 249 | Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. <i>Blood</i> , 2016, 128, 3171-3171. | 0.6 | 2 |
| 250 | Evolution of Therapy for Older Patients With Acute Myeloid Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> 16(10):1070-1076. 2010 | 1.6 | 2 |
| 251 | Role of epigenetic therapy in myelodysplastic syndrome. <i>Expert Review of Hematology</i> , 2008, 1, 161-174. | 1.0 | 0 |
| 252 | Novel Strategies in the Treatment of Older Patients with Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S51-S53. | 0.2 | 0 |